Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

  1. Casa
  2. Internacional
  3. Estados Unidos
  4. Austin
  5. Negocios (B2B)
  6. Negocios en venta
  1. Posted by: [email protected]
  2. Member since: June 2026
  3. Posted:
  4. Categoría: Negocios en venta
  5. Región: Austin (Astin)
  6. ID de Publicación: 63684214
Genentech’s Phase III Krascendo 1 trial shows divarasib significantly improves progression-free survival over approved KRAS G12C inhibitors in advanced NSCLC patients.

Austin, Businesses For Sale, Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
Atrás Próximo
Enviar un Correo Electronico a un Amigo

Ask AI to Review This Ad

¿Problemas con este anuncio?


How to Avoid Scams